Posts tagged ‘Pfizer’

December 10, 2013

Pfizer to expand clinical data access to researchers, patients


NEW YORK (Reuters) – Global drugmaker Pfizer Inc will broaden access to information from its scores of clinical trials to independent researchers and to patients who take part in the studies, the company said on Wednesday.

Pfizer, the largest U.S. pharmaceutical company, said it hoped the enhanced access to its data will help spur further scientific and medical research as well as encourage more patients to get involved in clinical trials.

“We are impressed to see how active patients are individually to manage and understand their disease, and in patient foundations a tremendous, great job is made to contribute to the advance of care,” Pfizer research chief Mikael Dolsten told reporters at the company’s New York headquarters. “We think this is the right time to support this trend.”

The move comes at a time of increasing pressure on the pharmaceutical industry to be more transparent with clinical trial information – including safety data and details of failed studies – and to increase access for the scientific community.

European health regulators announced a plan to start publishing clinical trial data submitted by companies seeking new drug approvals from next year, a move opposed by some drugmakers. Britain’s GlaxoSmithKline has set up an online system to provide researchers with access to anonymous patient-level data about its medicines.

See on news.yahoo.com

From Pharmaceutical Industry digital vision

Advertisements
Tags:
November 25, 2013

Novartis, Pfizer both developing hot new breast cancer treatment drug

Novartis’s experimental new breast cancer treatment drug, LEE011, was set to enter final-stage Phase III clinical trials next month.

LONDON (Reuters) – Novartis is hot on the heels of Pfizer in developing a promising new type of breast cancer drug that analysts believe could generate billions of dollars in annual sales.

The Swiss drugmaker, which has previously kept its research program under wraps, revealed on Friday that its experimental pill LEE011 was set to enter final-stage Phase III clinical trials next month.

Pfizer’s rival drug palbociclib – the first in the class – is already in Phase III testing, but Novartis’ rapid progress means the U.S. group could face competition sooner than expected. Both drugs are pills and work by blocking two enzymes known as cyclin dependent kinases (CDK) 4 and 6.

The significance of the new targeted approach to fighting cancer was highlighted in April when U.S. regulators granted a “breakthrough therapy” designation to palbociclib, based on impressive results seen in mid-stage trials.

Palbociclib is widely seen by investors as Pfizer’s most valuable compound in late-stage development and the company has started several new clinical trials to maximize its potential.

Analysts currently expect annual palbociclib sales of $1.9 billion by 2019, according to consensus estimates compiled by Thomson Reuters Pharma, and some think it could eventually sell $5 billion if it is approved for multiple cancer types.

Because Novartis has not previously revealed mid-stage clinical trial data for LEE011, analysts have not so far modeled sales forecasts for that product.

See on medcitynews.com

From Pharmaceutical Industry digital vision

November 4, 2013

Cancer : lancement d’un parcours de soin virtuel par Pfizer

Le laboratoire Pfizer lance un parcours de soin virtuel dans le cadre de son programme Personnalisation de l’ACcompagnement du patienT en ONCOlogie : PacT Onco. Présentation.

Pour permettre aux patients atteints de cancer de mieux comprendre la maladie et de se préparer aux différentes consultations, aux examens et aux traitements, le laboratoire Pfizer a développé le programme PacT Onco :  Personnalisation de l’ACcompagnement du patienT en ONCOlogie.

Dans le cadre de ce programme, le laboratoire Pfizer met à disposition un module interactif Parcours de Soins, conçu en collaboration avec des associations de patients, et accessible à l’adresse pactonco.pfizer.fr.

See on buzz-esante.com

From Pharmaceutical Industry digital vision

November 4, 2013

Le Viagra® à l’heure du générique : Allodocteurs.fr

Depuis sa mise sur le marché, en 1998, la ‘petite pilule bleue’ a déjà aidé, en France, plus d’un million d’hommes souffrant de troubles de l’érection.

C’est précisément la molécule du Viagra®, le citrate de sildénafil, qui depuis le 22 juin 2013 n’est plus protégée par un brevet. Le laboratoire Pfizer n’a plus l’exclusivité de la vente de cette molécule. La voie est donc désormais ouverte aux génériques.

Quand un médicament est génériqué, le volume des ventes du produit initial baisse considérablement. Pfizer entend donc limiter la casse en fabriquant lui aussi son propre générique. Le Viagra® générique version Pfizer est une pilule blanche, commercialisée sous le nom de “Sildénafil Pfizer”. Ce générique est produit sur les mêmes chaînes de fabrication que le médicament d’origine, dans l’usine d’Amboise, en Indre-et-Loire, avec exactement les mêmes contrôles, les mêmes processus, les mêmes ingrédients.

Les pilules incorporant le sildénafil restent délivrées uniquement sur prescription médicale. Ces génériques du Viagra® permettront une meilleure prise en charge des troubles de l’érection, se réjouissent les médecins, qui voyaient jusque-là un frein économique à la prescription du traitement. L’arrivée des génériques du Viagra® ouvre donc de nouvelles perspectives en démocratisant un médicament encore tabou.

See on www.allodocteurs.fr

From Pharmaceutical Industry digital vision

October 28, 2013

Un million de faux comprimés de Xanax saisis à Zurich

Les douanes suisses ont mis la main, à l’aéroport de Zurich (Suisse), sur un important stock de médicaments contrefaits, contenant un million de faux comprimés de Xanax, selon un communiqué publié vendredi par Swissmedic, l’autorité de contrôle des médicaments. Les comprimés imitant l’antidépresseur de Pfizer venaient de Chine et étaient destinés à l’Égypte, via la Suisse. Les douaniers ont saisi quatre palettes de médicaments contrefaits pesant plus de 400 kg chacune et alerté Swissmedic qui a analysé la prise. Les analyses effectuées par les laboratoires de Swissmedic ont révélé que ces médicaments ne contiennent aucun principe actif. Selon Swissmedic, les contrefaçons sont indécelables au premier coup d’œil. Swissmedic a alerté les autorités internationales, et en particulier les autorités sanitaires égyptiennes et chinoises, et ordonné la destruction de la marchandise. f

See on www.lequotidiendupharmacien.fr

From Pharmaceutical Industry digital vision

Tags: ,
September 25, 2013

Pfizer launches trial data sharing service | Pharmafile

Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, jobs, events, and service company listings.

Pfizer has launched a first-of-its-kind project that enables patients who have participated in clinical trials the ability to download their individual clinical data. 

Using the Blue Button standard, an initiative first launched by the White House in 2010, patients “will be empowered to use the data to improve their overall health and wellness, from sharing with healthcare providers to powering clinical risk assessments”, according to Pfizer.

Announced at this year’s Dpharm ‘disruptive innovations’ conference in Boston, US, Pfizer’s new project comes at a time when clinical trial transparency is becoming a major issue.

Allowing the digital sharing of data via the Blue Button is a new way forward for pharma, but falls short of allowing independent scrutiny of all study data, something being called for in the UK and Europe.

Typically as clinical trials conclude results are posted online and published in scientific journals, but little information is routinely given back to the patient to acknowledge their contribution.

But new data shows that over 90% of patients with access to a personally controlled health record are willing to share that data for research. Pfizer says that early results from its new project demonstrates the ability of research sponsors to engage patients in this new ecosystem, by first sharing their data with patients setting “a new standard for trust and collaboration”.

The Blue Button is a literal button appearing on many websites that lets consumers get their health information online.

The US Veterans Administration (VA) was first to display the Blue Button symbol on its patient portal in 2010 – it allows US military veterans the ability to click on the Blue Button icon to securely download their health informationelectronically.

See on www.pharmafile.com

From Pharmaceutical Industry digital vision

Tags:
August 18, 2013

How Is Social Media Reshaping Pfizer? | Social Media Today

I had a chance to sit down with Bob Libbey, head of Digital and Social Communications at Pfizer, to discuss some of the topics that you will see at the Social Shake-Up Conference.

I had a chance to sit down with Bob Libbey the Head of Digital and Social Communications at Pfizer to discuss some of the topics that you will see at the Social Shake-Up Conference. The following is a transcript of our conversation. Enjoy!

SMT:   Tell me how a company like Pfizer organizes all the social efforts going on across the organization.

BOB:   The efforts are largely concentrated at the corporate level right now. We are organized operationally by business units that serve their discreet markets and also do some social, and by supporting functions and platform functions.

SMT:   It’s got to be difficult because you’ve got a lot of regulation facing you.  Can you talk a little bit about the difficulties that you have versus say a technology company that doesn’t have these kinds of regulations?

BOB:   Interestingly enough the issue for pharma is largely a lack of regulation or guidance regarding social media, so we as a company have developed our own policies and procedures around our use of social media to ensure we’re compliant, of course, and running our channels according to best practices.

See on socialmediatoday.com

From Pharmaceutical Industry digital vision

August 4, 2013

Pfizer’s New Structure Could Be The Prelude To A Breakup

Pfizer CEO Ian Read The world’s largest drug company took another step in a multi-year dance that could end up with it splitting into pieces.

Each with its own top executive who will report to Chairman and Chief Executive Ian Reed. They will include:

An “innovative” business segment led by Geno Germano, who will be a Group President, which will include most products that will still be protected by patents after 2015. This will include inflammation, immunology, heart disease and diabetes, neuroscience and pain, rare disease, and men’s and women’s health.Vaccines, oncology, and consumer products will go in a separate division run by Amy Schulman, who was until now Pfizer’s general counsel but who also had authority over the consumer division. She will also be a Group President. How did those three divisions get split out on their own? Pfizer spokeswoman Joan Campion says they have “distinct operating models” with regard to other disease areas. Vaccines often rely on innovation campaigns and government endorsements; oncology is increasingly shaped by the academe; consumer products are sold over the counter.A “value” business segment will be led by John Young that will market products that don’t rely on patent protection, like Lipitor (off-patent, but it is expected to generate $2 billion in sales this year) as well as generic versions of biotech drugs, known as biosimilars, and partnerships in Japan, Brazil, and China. This is the division that most people on Wall Streetexpect to be spun off in 2017 or later, raising cash for the higher-growth science businesses.

See on www.forbes.com

From Pharmaceutical Industry digital vision

Tags:
July 30, 2013

Pfizer Reports Second-Quarter 2013 Results | Pfizer Pharmaceutical News and Media | Pfizer: the world’s largest research-based pharmaceutical company

 

Pfizer Reports Second-Quarter 2013 ResultsResults Reflect the Animal Health Business (Zoetis(1)) as a Discontinued Operation for Second-Quarter and Year-to-Date 2013 and 2012Second-Quarter 2013 Revenues of $13.0 Billion, Adjusted Diluted EPS(2) of $0.56 and Reported Diluted EPS(3) of $1.98Repurchased $3.3 Billion and $8.7 Billion of Common Stock in Second-Quarter and to Date in 2013, RespectivelyAccepted 405.1 Million Shares of Common Stock in Exchange for Remaining Zoetis(1) InterestReaffirmed All Components of Adjusted Financial GuidanceAnnounced Plan to Create Separate, Internal, Global Innovative and Value Businesses Tuesday, July 30, 2013 3:49 am EDT

See on press.pfizer.com

From Pharmaceutical Industry digital vision

Tags: